Agomelatine targets a range of major depressive disorder symptoms

Curr Opin Investig Drugs. 2006 Jul;7(7):670-80.

Abstract

Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.

Publication types

  • Review

MeSH terms

  • Acetamides / adverse effects
  • Acetamides / metabolism
  • Acetamides / pharmacokinetics
  • Acetamides / therapeutic use*
  • Acetamides / toxicity
  • Animals
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / metabolism
  • Antidepressive Agents / pharmacokinetics
  • Antidepressive Agents / therapeutic use*
  • Antidepressive Agents / toxicity
  • Anxiety / psychology
  • Circadian Rhythm / physiology
  • Clinical Trials as Topic
  • Contraindications
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / psychology
  • Drug Evaluation, Preclinical
  • Humans
  • Receptors, Melatonin / drug effects
  • Receptors, Serotonin / drug effects
  • Sleep / drug effects
  • Sleep Initiation and Maintenance Disorders / drug therapy
  • Structure-Activity Relationship

Substances

  • Acetamides
  • Antidepressive Agents
  • Receptors, Melatonin
  • Receptors, Serotonin
  • S 20098